Shots: The A P-IIb study involves assessing of dapirolizumab pegol vs PBO in adults with moderate-to-severe SLE despite receiving SoC treatment, evaluating safety and efficacy The study demonstrated unmet 1EP @24 wks. on the BICLA and showed improvements in majority of clinical endpoints, with safety and tolerability Dapirolizumab pegol is an anti-CD40L pegylated Fab jointly […]Read More
